Table 1.
Overall Survival and Regression-free Survival data from some studies with a great number of patients with PPME.
| Author(s) | Number of Patient | Treatment | Overall Survival (OS) | Recurrence-Free Survival (RFS) | Future Prospectives |
|---|---|---|---|---|---|
| Hashimoto [306] | 6 | Surgery 4 ICI (2) |
19.6 (6.4–40.5) months | 19.3 months (range, 3.9–37.9) | Additional studies |
| Wang [276] | 76 | Surgery 59 Adjuvant therapy 37 |
22.3 months | 4.5 months | PD-1 valuable option for therapy |
| Lasota [278] | 16 (data available) | Surgery 16 | 4–22 months | / | New studies about NGS |
| Cheng [281] | 9 | Surgery 5 PR 1 Chp 1 ICI 1 Biotherapy 1 |
OS stage I: 100% OS stage OS stage III-IV: 0% |
/ | More randomized controlled trials |
| Dai [285] | 70 | Surgery/adjuvant chemotherapy | 13.5 months | / | / |
| Kim [302] | 17 | Surgery 10 Chemotherapy/ICI 7 |
10 months | 4 months | Further large-scale studies are required regarding novel treatment strategies such as immunotherapy for patients with PMME |
Legend. PR: Palliative Resection; Chp: chemotherapy post-operatory; ICI: Immunocheckpoint inhibitors.